RETROSPECTIVE ANALYSIS OF THE INHIBITOR FORM OF HEMOPHILIA A IN CHILDREN
Keywords:
hemophilia A, inhibitor form, factor VIII, Bethesda units, inhibitor antibody titerAbstract
Baseline factor VIII activity level cannot serve as a reliable clinical predictor of inhibitor development. Given the high frequency of this complication, regular laboratory screening for antibodies is justified for all patients receiving replacement therapy, regardless of the severity of the disease phenotype.
References
Rumyantsev AG. Hemophilia A: challenges of real clinical practice. Russian Journal of Pediatric Hematology and Oncology. 2020;7(4S):3–6. (in Russ).
National Clinical Protocol for the Diagnosis and Treatment of Hemophilia A and B. Clinical Protocols 2024. Uzbekistan; 2024. (in Russ).
Rumyantsev AG, Zozulya NI, Zorenko AYu, et al. Diagnosis and treatment of hemophilia: national clinical guidelines. Moscow: National Medical Research Center for Hematology of the Ministry of Health of Russia; 2024. (in Russ).
Pshenichnikova OS, Surin VL. Genetic risk factors for the development of inhibitor hemophilia A. Genetics. 2021;57(8):859–870. (in Russ).
Zozulya NI, Chernov VM, Tarasova IS, Rumyantsev AG. Unresolved issues in medical care for patients with inhibitor hemophilia in Russia. Russian Journal of Pediatric Hematology and Oncology. 2019;6(2):48–53. (in Russ).
Barlamov PN, Vasilyeva ER, Golubeva ME, Zhelobov VG, Starikova OS, Shutylev AA. Acquired inhibitor hemophilia. Clinical Medicine. 2018;96(4):361–364. (in Russ).
Dmitriev EV, Lyubushkin AV. Medical prevention of inhibitor hemophilia A in high-risk patients. Hematology Transfusiology Eastern Europe. 2024;10(3):296–305. (in Russ).
